OAOdile Audrain

Odile Audrain

*This is an algorithmically generated author record based on publicly available information.

Odile Audrain has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • En reconstruction mammaire : intérêt du dépistage du portage de Staphylococcus aureus dans la prévention de l’infection du site opératoire

    by S. Rouquette, F. Cherrière, A. Vagneur, F. Godey, S. Sun, A. Jolivet-Gougeon, H. Mesbah, O. Audrain, C. Bendavid


    • 1 September 2013
      • Vol. 33  (9) , 3871-7

    In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.

    by Marc Pracht, Julien Edeline, Nicolas Lepareur, Laurence Lenoir, Valerie Ardisson, Bruno Clement, Jean-Luc Raoul, Odile Audrain, Evelyne Boucher, Etienne Garin

    Hepatocellular carcinoma is generally diagnosed at advanced stages, for which only palliative treatments are possible by intra-arterial route or by targeted therapies. Among these treatments, metabolic radiotherapy using (90)-yttrium or (188)Re and sorafenib are two options adopted in monotherapy. We address the question of a possible synergy arising from the combination of these two treatments. Two primary malignant hepatoma cell lines, N1S1 (murine HCC) and HepG2 (human hepatoblastoma) were treated in media containing increasing concentrations of sorafenib with/without (188)Re to assess the cellular toxicities of each treatment alone and in combination. The combination index method was used to look for synergy or additivity. A synergistic advantage of a treatment combining (188)Re and sorafenib is shown in vitro on hepatoma cell lines. This combined approach is promising and now needs to be confirmed by more complex in vitro models integrating the tumoral stroma, as well as by in vivo studies.


  • Open Access

    Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results

    by M. Pracht, J. Edeline, L. Lenoir, M. Latournerie, H. Mesbah, O. Audrain, Y. Rolland, B. Clément, J. L. Raoul, E. Garin, et al.

    Portal vein tumor thrombosis (PVTT) is a common complication of hepatocellular carcinoma (HCC) and has a negative impact on prognosis. This characteristic feature led to the rationale of the present trial designed to assess the efficacy and the safety of yttrium-90 glass-microsphere treatment for advanced-stage lobar HCC with ipsilateral PVTT. 18 patients with unresectable lobar HCC and ipsilateral PVTT were treated in our institution with90Y-microS radioembolization. Patients were evaluated every 3 to 6 months for response, survival, and toxicity. Mean follow-up was 13.0 months (2.2–50.6). Outcomes were: complete response (n=2), partial response (n=13), stable disease (n=1), and progressive disease (n=2) giving a disease control rate of 88.9%. Four patients were downstaged. Treating lobar hepatocellular carcinoma with ipsilateral portal vein thrombosis with yttrium-90 glass-microsphere radioembolization is safe and efficacious. Further clinical trials are warranted to confirm these results and to compare90Y-microS with sorafenib, taking into account not only survival but also the possibility of secondary surgery for putative curative intention after downstaging.


  • Metastatic melanoma: results of ‘classical' second-line treatment with cytotoxic chemotherapies

    by Christophe Perrin, Marc Pracht, Karen Talour, Henri Adamski, Isabelle Cumin, Marc Porneuf, Marie Talarmin, Habiba Mesbah, Odile Audrain, Aline Moignet, et al.

    Background: Metastatic melanoma is one of the most aggressive tumours, with a median survival that does not exceed 12 months. None of the cytotoxic first-line therapies have shown survival benefit in randomised clinical trials. Objective: To describe clinical benefit of second-line cytotoxic chemotherapy in the second line of treatment for metastatic melanoma. Methods: In a retrospective study, we analyse the outcome of patients with metastatic melanoma who had received two lines or more of cytotoxic treatments in four French dermato-oncology departments between 1999 and 2009. Results:We describe the outcomes for 109 patients. Most of these patients received dacarbazine for the first line of chemotherapy and fotemustine for the second line of chemotherapy (67.0 and 64.2%, respectively). A clinical benefit was observed in 24.1% of the patients and overall survival was 4.1 months after the second-line treatment. At least 23.8% of patients suffered from grade 3 or 4 toxicities. The presence of more than two sites of metastasis and an M1c staging according to the AJCC classification represented negative predictive factors of clinical benefit. Conclusion: This study shows the modest benefit of a second line of cytotoxic chemotherapy in a nonselected population. If eligible, these patients should be proposed for ongoing clinical trials or for targeted therapies.


  • Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma

    by Laurence Crouzet, Julien Edeline, Fanny Le Du, Eveline Boucher, Odile Audrain, Jean-Luc Raoul


    • 1 May 2009
      • Vol. 29  (5) , 1697-701

    Prognosis for isolated skin recurrence after breast cancer treated by mastectomy.

    by Frederique Jaffre, Vincent Lavoue, Habiba Mesbah, Sophie Rouquette, Odile Audrain, Jean François Laurent, Jean Leveque

    Isolated skin recurrence after mastectomy (ISRAM) for breast cancer is a rare event for which treatment is difficult and subject to debate. The records of 75 patients presenting with ISRAM were reviewed retrospectively. The factors liable to affect recurrence prognosis were analyzed, and included both factors related to the primary tumor and its treatment and those related to the recurrence itself. The size of the primary tumor is correlated with the inflammatory nature of the recurrence as well as overall survival. Metastatic lymph node involvement also affects the risk of inflammatory recurrence and is correlated with overall survival. Salvage mastectomy for local recurrence after primary breast-conserving surgery followed by ISRAM has a poor prognosis in terms of recurrence-free survival, and chest wall radiotherapy after primary mastectomy reduces the risk of metastatic development after ISRAM. When confronted with ISRAM, 2 factors affect prognosis: the inflammatory nature of the recurrence impairs overall survival and chest wall radiotherapy reduces the risk of secondary systemic disease. these results underline the importance of good local control when treating the primary tumor (to reduce the risk of ISRAM occurrence, and improve its prognosis if it occurs) and the advantage of locoregional and systemic treatment in the presence of ISRAM and in particular its inflammatory presentation.